Table 1 Sample counts by tissue and prior chemotherapy exposure
From: Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer
| Â | Patients | Samples (with an untreated sample from same patient) | ||||
|---|---|---|---|---|---|---|
| Â | Â | Solid tissue | Ascites | Total | Â | |
Primary/untreated | 76 | 75 | 4 | 79 | Â | |
Primary/treated | 5 | 5 (0) | 0 (0) | 5 (0) | Â | |
Relapse/treated | 23 | 6 (4) | 24 (10) | 30 (14) | Â | |
Total | 92 | 86 (4) | 28 (10) | 114 (14) | Â | |
| Â | Carboplatin | Cisplatin | Cyc. | Etoposide | Gemcitabine | Paclitaxel |
Primary/treated | 5 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0) | 4 (0) |
Relapse/treated | 30 (14) | 5 (2) | 10 (6) | 1 (1) | 17 (8) | 30 (14) |
Total | 35 (14) | 5 (2) | 10 (6) | 1 (1) | 18 (8) | 34 (14) |